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Abstract: The potential of nitric oxide (NO) as a rapid assay biomarker, one that could provide a quantum leap in acute 
care, remains largely untapped. NO plays a crucial role as bronchodilator, vasodilator and inflammatory mediator. The 
main objective of this review is to demonstrate how NO is a molecule of heavy interest in various acute disease states 
along the emergency department and critical care spectrum: respiratory infections, central nervous system infections, 
asthma, acute kidney injury, sepsis, septic shock, and myocardial ischemia, to name just a few. We discuss how NO and 
its oxidative metabolites, nitrite and nitrate, are readily detectable in several body compartments and fluids, and as such 
they are associated with many of the pathophysiological processes mentioned above. With methods such as high 
performance liquid chromatography and chemiluminescence these entities are relatively easy and inexpensive to analyze. 
Emphasis is placed on diagnostic rapidity, as this relates directly to quality of care in acute care situations. Further, a 
rationale is provided for more bench, translational and clinical research in the field of NO biomarkers for such settings. 
Developing standard protocols for the aforementioned disease states, centered on concentrations of NO and its 
metabolites, can prove to revolutionize diagnostics and prognostication along a spectrum of clinical care. We present a 
strong case for developing these biomarkers more as point-of-care assays with potential of color gradient test strips for 
rapid screening of disease entities in acute care and beyond. This will be relevant to global health.  
Keywords: Acute kidney injury, Acute myocardial ischemia, Acute respiratory illness, Asthma,  Critical care, Emergency 
department, Nitrate, Nitrite, Nitric Oxide, Sepsis, Shock. 
INTRODUCTION 
 The emergency department (ED), closely linked to the 
critical care setting, is widely used as first and last resort for 
acute as well as chronic disease management. In fact, with 
the advent of the economic recession in the U.S. and 
concomitant loss of health insurance in families, usage of the 
ED has increased tremendously [1, 2]. The ED and critical 
care settings provide a unique clinical venue to develop, test 
and implement novel biomarkers that can be cost-effective 
and rapid in their ability to manage acute as well as chronic 
disease processes with acute exacerbations. Much of the 
current laboratory testing is cost and time inefficient and 
presents detectable amounts of the biomarker only in the 
later periods of the pathological cycle. For example, the most 
prevalent traditional biomarker of renal dysfunction and the 
gold-standard, serum creatinine, can take up to 72 hours to 
rise in early acute renal failure (acute kidney injury); 
baseline levels may be unavailable, thus it renders itself as a  
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biomarker with limited utility in the acute setting [3, 4]. 
There is an unmet need for viable and rapid biomarkers for 
various acute disease states, such as bronchiolitis, asthma, 
influenza-like illness (with increased numbers during 
pandemics), sepsis, shock, cardiovascular-related acute 
ischemia / injury in the coronary and cerebral vasculature, to 
name a few. Thus, these novel biomarkers can potentially 
enhance disease management in a variety of clinical settings.  
 Nitric oxide (NO) and its metabolites, as potential 
signaling molecules, are implicated in a wide variety of 
physiological and pathological states. This review will cover 
some of the more recent progress made in establishing the 
utility, and limitations, of NO and its metabolites, nitrite and 
nitrate, in a few acute disease states. The utility of these will 
be extrapolated to disease processes beyond the ED, i.e., to 
the critical care setting, along a continuum of care.  
NITRIC OXIDE AND ITS METABOLITES: PHYSIOL-
OGICAL AND BIOCHEMICAL ASPECTS 
 NO as a highly reactive gaseous signaling molecule and 
free radical is implicated in a variety of physiological and 
biochemical processes (Fig. 1). Although it has been 
associated with virtually every organ system in the body, it’s 
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most important roles are 3 fold: regulation of blood flow in 
the vascular endothelium (vascular homeostasis), neurotran-
smission and host defense mechanisms [5].  
 The predecessor to part of NO produced in the body is 
the semi-essential amino acid L-arginine (Fig. 2). NO 
production is catalyzed by 3 isoforms of NO synthase 
(NOS): endothelial or eNOS by vascular endothelium in the 
cardiovascular system, neuronal or nNOS, primarily 
operational in producing NO as a neurotransmitter, and 
inducible or iNOS, produced by a variety of cells 
(endothelial and otherwise) for a variety of reasons, 
including an immune-mediated or inflammatory response 
[6]. Both the calcium dependent NOSs (eNOS and nNOS), 
have transient activities and thus exhibit relatively low 
concentrations, usually ranging in the nM range, while the 
Fig. (1). Nitric oxide (NO): Diversity in action. 
Fig. (2). The nitric oxide (NO), nitrite (NO2-) and nitrate (NO3-) cycle. Formation of NO, oxidation to nitrite and nitrate (collectively, NOx), 
and their potential as biomarkers for disease processes in the acute care setting. Acute kidney injury (AKI); Cerebrospinal fluid (CSF); 
Central nervous system (CNS); Cyclic guanylate monophosphate (cGMP); Fractional excretion of nitric oxide (feNO); Guanylate 
triphosphate (GTP); Nitric oxide synthase (NOS); Soluble guanylate cyclase (sGC). 
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cytokine activated, calcium independent, iNOS is long 
lasting, generating higher concentrations of NO, usually in 
the µM range [6]. As a vascular effector, NO rapidly diffuses 
from its site of generation in endothelial cells into adjacent 
smooth muscle cells, where it activates soluble guanylate 
cyclase (Fig. 2). The latter enzyme converts GTP to cGMP, 
the second messenger that affects vascular smooth muscle 
relaxation [7].  
 Once produced and active, NO can exist as the nitrosium 
cation (NO+), the nitroxyl anion (NO-), and a NO free 
radical (all with half lives < 20 s in circulation); all of these 
forms then undergo a sequential oxidation or nitrosation of 
water to form the more stable NO metabolites, nitrite 
[t1/2=110 s in blood] and nitrate [t1/2=5-8 h in blood] [8] (Fig. 
2). Fig. (2) also shows that nitrate and nitrite (collectively 
referred to as NOx) can be recycled to produce NO (via 
reduction) in various ways, one of which is the 
enterosalivary circulation of endogenous nitrate, an essential 
pathway in maintenance of NO homeostasis [8-11]. NOx in 
blood as an index of eNOS activity has been widely used as 
routine indirect measure of NO levels [12-15]. Recent 
studies have indicated that nitrite is an important signaling 
molecule in its own right [16, 17]. Since it can be reduced 
back to NO given appropriate circumstances, this has led to 
intense interest in this relatively simple molecule [18]. A 
significant contribution of circulating levels of NOx is from 
dietary intake of those moieties, and these can vary 
tremendously from diet to diet [8]. During fasting conditions 
with low dietary intake of NOx, enzymatic formation of NO 
via NOS accounts for the majority of circulating NOx. 
Nitrate and nitrite have been shown to be biomarkers for 
cardiovascular and other diseases from both diagnostic and 
therapeutic aspects [6, 8]. In addition to blood, urinary levels 
of NOx provide a means to assess systemic production of 
NO in vivo, however, with the caveat that urinary (or 
plasma) levels are truly reflective of endogenous production 
of NO, dietary ingestion of NOx, as well as from bacterial 
activity in the gut [6, 8].  
 The interaction of NO and NOx with other moieties such 
as superoxide (to form peroxynitrite), thiols (to form S-
nitrosothiols), secondary amines (to form N-nitrosoamines), 
and metals (to form nitrosyl-heme) is also important 
physiologically. As a free radical NO is bactericidal at 
baseline, however, it has the additional property of 
scavenging superoxide and by doing so protects against 
injury [6]. The double edged nature of this reaction though is 
evidenced by the resultant peroxynitrite, a potent cytotoxic 
agent, implicated in disease processes, and an area of intense 
research effort [19].  
NO AND ITS METABOLITES IN ACUTE DISEASE 
PROCESSES 
NO and its Metabolites as Markers of Ongoing Infection 
and Inflammation 
 In addition to the various physiological and biochemical 
properties and functions described above, NO can also be a 
biomarker for many inflammatory disease states, either local 
to the tissue where generated or systemically. The effects of 
NO as an inflammatory mediator have been studied in detail 
for a length of time. NOS and NO induction have been 
shown to be innate immune effectors of infectious/inflam-
matory pathways [20]. The precise effect that NO has on 
these disease states and inflammatory mediation is still under 
debate. A recent study showing the temporal effects of NO 
metabolites in a rodent model of systemic inflammation and 
sepsis revealed tissue specific and time specific changes in 
NO metabolites [21]. This highlights ‘the NO paradox’: is 
NO a helpful mediator in inflammatory disease, or does it 
function as a cytotoxic effector of non-specific immune 
response? In a ‘too much of a good thing’ scenario, during 
the immune response, moderate levels of NO prove 
beneficial to the organism, while excess levels lead to too 
much potency and thus damage.  
NO and its Metabolites in Acute Respiratory Infections 
 Respiratory syncytial virus (RSV) and influenza can 
cause major respiratory infections. RSV is the most common 
cause of lower respiratory tract infections in children, 
including bronchiolitis and pneumonia [22, 23]. There is a 
broad spectrum of disease severity for bronchiolitis, the 
leading cause of hospitalization for infants in the U.S. with 
associated hospitalization costs in excess of $500 million per 
year, as well as responsible for frequent ED visits [24, 25]. 
Pandemics like the 2009 novel swine-origin influenza A 
(H1N1) virus (nH1N1) pose significant challenges: increased 
transmission relative to seasonal influenza, severe disease in 
patients with medical co-morbidities, and difficulty in 
predicting which patients with viral respiratory symptoms 
are at risk for influenza complications [26]. In the evaluation 
of acutely ill patients with respiratory infections, risk 
stratification may be achieved by utilizing biomarkers, 
augmenting clinical decision-making, thus improving 
outcomes. This is particularly relevant to the acute care 
setting. 
 During influenza virus infection, epithelial cells, 
macrophages, lymphocytes and other cells release a complex 
series of cytokines and chemokines in an attempt to 
overcome viral replication and disease progression [27-29]. 
NO, a key mediator of airway inflammation is also released. 
It is unclear if increased NO activity is a marker of clinical 
disease, of the innate antiviral response, or associated 
significantly with a unique respiratory virus infection [30]. 
In the murine model of RSV for instance, NO production in 
the lungs appears to be associated with viral clearance and 
lung disease [31]. iNOS activity and production of NO were 
associated with enhanced clearance of RSV, yet they were 
also associated with airway inflammatory changes and 
airway dysfunction [31]. In murine studies of experimental 
influenza A-triggered pneumonia, excessive NO 
biosynthesis, as measured by its metabolites nitrate and 
nitrite, was demonstrated in the lungs [32, 33]. This 
suggested that the metabolites may be markers of influenza-
mediated disease in the respiratory tract.  
 In humans, NO is produced in the upper and lower 
respiratory tract. It can be detected in exhaled air of healthy 
individuals and at increased levels in subjects with 
pulmonary disease, including asthma (see below), 
bronchiectasis and upper respiratory infections [34-38]. In 
aqueous solutions, NO is rapidly converted to distinct oxides 
of nitrogen, which may thus be potential biomarkers of 
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disease severity in acutely ill patients presenting with 
influenza-like-illness (ILI) [35, 39]. During the 2009 nH1N1 
pandemic, we collected nasal wash specimens from children 
with acute ILI, and then measured NOx concentration in the 
nasal secretions by HPLC. Overall, our data suggested that 
concentration of NO-derived nitrate in nasal secretions in 
children may be related to type of viral pathogen causative 
for acute ILI: RSV subtype B-associated ILI had higher 
nasal wash nitrate compared to all other viruses combined 
(P=0.002) [40]. Ongoing studies will determine the 
predictive potential of this putative biomarker for important 
disease outcomes in sicker patients requiring critical care.  
 Exhaled NO has been studied as a putative biomarker for 
respiratory infections caused by influenza, rhinovirus and 
other viral pathogens, but the data have been equivocal [41, 
42]. The conflicting data above may simply reflect technical 
issues in measuring exhaled NO. This methodology is 
cumbersome to achieve in the pediatric population, either in-
patient or ED. The newer NIOX-MINO hand-held NO 
detector has proven to be as reliable as the older, stationary 
chemiluminescence analyzer, the Ecomedics (ECO) [43]. Its 
portability may make it easier to handle in acute care settings 
of the ED or critical care. Focusing on stable NO metabolites 
in nasal secretions from patients with acute ILI may still be 
the better approach because of ready accessibility. Future 
studies are needed that can establish correlations between 
nasal secretion NOx and exhaled NO for acute ILI either in 
the ED or critical care settings.  
NO and its Metabolites in Acute Central Nervous System 
(CNS) Infections  
 Meningitis can be a severe infection of the CNS. 
Bacterial meningitis, in particular, remains an important 
public health problem worldwide, with several studies 
confirming the devastating neurological sequelae that may 
result from it [44]. Cases of varying severity are likely to 
pass through the ED; and the more severe ones then sent to 
critical care. Early cerebrospinal fluid (CSF)-based 
biomarkers are needed that may be able to predict severity, 
so that potentially sicker patients can then get critical care 
support. NO and its metabolites in the CSF may represent 
such a biomarker. Studies have shown that patients admitted 
to the hospital with bacterial meningitis and influenza-
associated encephalopathy had higher levels of CSF NOx as 
compared to controls [45]. In another study, patients with 
RSV infection and symptoms of encephalitis, encephalo-
pathy or seizures were found to have a higher concentration 
of CSF NOx compared with those with influenza positive 
encephalopathy or those without meningitis [46]. Neither 
were the studies set up in the ED nor did they analyze CSF 
NOx in meningitis from different pathogens in the same 
setting. Using a rapid HPLC-based assay for detection of 
these metabolites in CSF in the acute setting may add to the 
current armamentarium for helping in early diagnosis of 
different forms of meningitis and may be predictive of 
disease severity. Detecting CSF NOx in a rapid assay may be 
particularly helpful in cases that are difficult to interpret, 
such as in cases of CSF pleocytosis. The added information 
may help guide management, ultimately resulting in better 
disease outcomes.  
NO in Acute Asthma Exacerbations 
 Asthma is a major public health issue [47]. Acute asthma 
exacerbations are common causes for pediatric and adult ED 
visits with significant morbidity and mortality associated 
with them [48]. Prompt diagnosis and treatment in the ED 
and beyond are needed. There are no definitive diagnostic 
and predictive tests for asthma, specifically in the acute 
setting. NO is thought to play an important role in the 
pathogenesis of asthma by modifying airway hyper-
reponsiveness and inflammation. Studies in asthmatic 
children and adults have shown that fractional excretion of 
nitric oxide (feNO) reflects the degree of airway 
inflammation, with higher levels correlating with severity of 
disease, likely secondary to inflammation. As such, it can be 
a non-invasive biomarker for severity of the disease process 
and response to treatment [49-51]. In several studies the 
adequacy of anti-inflammatory treatment for chronic asthma 
has been demonstrated by lowered concentration of feNO 
[52-55], indicating the potential of NO as a management tool 
for asthma. Based on this, Kwok et al. performed a cross-
sectional study in children 2-18 years of age presenting to an 
urban ED with an acute asthma exacerbation [56]. Using a 
tidal breathing method and a chemiluminescence-based NO 
analyzer, they showed that only 68% of the subjects could 
provide adequate breaths for feNO measurements [56]. 
Furthermore they showed that this method had limited utility 
in the acute management of childhood asthma. A more 
definitive answer for the utility of feNO in the acute setting 
may be obtained in a study that follows the patients over a 
longer duration than the typical 2-4 hour period covered by 
Kwok et al. [56]. Although it may have been harder for 
children to manage the respiratory maneuvers for the feNO 
determination, it may be a more reliable tool for the adult 
asthmatic population in acute care settings. Finally, an easier 
to use device may be the answer. More recently, the portable 
NIOX-MINO, mentioned above, has shown a high 
correlation (r = 0.97, P < 0.001) with the more conventional 
chemiluminescence device (NIOX) [57]. More encouraging 
was that in the 55 children enrolled (4-9 years of age), up to 
73% successfully provided feNO measurements, and thus 
this may be a better tool for screening as well as 
management of acute asthma in the pediatric and adult 
population [57].  
 Since NO is a ubiquitous signaling molecule, pertur-
bations in the NO pathway in the asthmatic airway over time 
may be reflected in changes in levels of NO metabolites 
measured elsewhere, such as plasma and urine. Determining 
ratios between the levels of NO and its metabolites by 
sampling different compartments may reveal a time course 
reflecting evolution of the disease. Thus we may be able to 
monitor NO from different compartments in different 
settings (first in the ED and then during critical care) and at 
different times indicating its biomarker potential for asthma 
severity and management. Having better tools to diagnose, 
predict and manage an acute asthma exacerbation would help 
reduce the burden of this illness, particularly in the pediatric 
population that is disproportionately affected by this 
problem.  
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NO and its Metabolites in Acute Kidney Injury  
 Acute kidney injury (AKI) is a common complication 
among ambulatory and hospitalized patients, and can cause 
significant morbidity and mortality, specifically in patients in 
critical care medicine [58-61]. Patients, including pediatric 
ones, who are or will get critically ill from AKI are likely to 
pass through the ED [3, 4]. As alluded to in the introduction 
to this review, the conventional biomarker for AKI, namely 
serum creatinine, can take up to 3 days for an elevation or 
change from baseline, indicative of worsening renal function 
[60, 62, 63]. Thus, additional early biomarkers are needed 
that can be diagnostic and prognostic of AKI in the ED and 
critical care settings, at a time when baseline serum 
creatinine is either unavailable or uninformative. NO has 
been shown to have several functions in the kidney, 
depending on its concentration, site of release, and duration 
of action [64]. Endothelial injury and the subsequent 
microcirculatory dysfunction is likely a primary event in 
renal hypoxia with disturbances in NO-related pathways 
playing key roles [65]. In an adult post-ischemic model of 
AKI urinary concentration of NO (as measured by its 
metabolites nitrate and nitrite) were markedly lower 
suggesting that this was a reflection of potential endothelial 
damage in the kidney [66]. Thus, we conducted a study to 
test the hypothesis that urinary concentration of nitrate and 
nitrite would be decreased in early AKI in children 
presenting to the ED [4]. We showed that in 252 patients, 0-
19 years of age presenting to the pediatric ED, lower 
concentration of urinary nitrate, but not nitrite, was 
significantly associated with AKI (Fig. 3), thus indicating the 
potential for this as a novel urinary biomarker for AKI in the 
ED [4]. More encouraging was the potential for this urinary 
biomarker in the face of a normal serum creatinine in almost 
half of those with AKI [4]. Future studies are needed to 
evaluate fully the ability of urinary nitrate to predict 
important in-patient clinical outcomes, such as critical care 
needs, dialysis, and ultimately mortality. As mentioned 
above, urinary NO metabolites are a reflection of both 
dietary intake of NOx as well as endogenous generation of 
NO, thus additional studies are needed to determine whether 
diminished level of urinary nitrate in AKI is truly indicative 
of renal endothelial dysfunction.  
NO and its Metabolites in Sepsis and Septic Shock  
 Sepsis is defined as the systemic response to infection, 
and about half of those patients progress to septic shock 
characterized by refractory hypotension and multiple organ 
failure [6]. Severe sepsis and septic shock are associated 
with significant mortality, as high as 28% [67]. 
Hemodynamically, both macro- as well as microcirculatory 
failure is the hallmark of severe sepsis and septic shock [67]. 
Fig. (3). Urinary nitrate distinguishes patients with acute kidney injury (AKI) from those either at risk or without AKI. Data based on ref. [4], 
shows median urinary nitrate normalized to urinary creatinine in patients presenting to TCH [N=252]. Bar on left represents combined no 
AKI and at risk for AKI, whereas the one on the right represents those with AKI. Data are shown as box plots with the heavy line in the box 
representing the median (50th percentile) and the ends of the box representing 25th and 75th percentiles, respectively. Groups were compared 
using the non-parametric Mann Whitney U test (*P=0.02). Cr, creatinine. TCH, Texas Children’s Hospital.  
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The central role of NO in maintaining microcirculation is 
highlighted in sepsis and septic shock, states in which the 
microcirculation has sustained an insult. Several studies have 
implicated the overproduction of NO as the cause for the 
decompensated state [6]. Sepsis, septic shock or systemic 
inflammatory response syndrome in intensive care settings is 
associated with increased plasma nitrate and nitrite [68-70]. 
Measuring both plasma and urinary NOx has revealed 
elevations in patients with sepsis and septic shock [6]. Innate 
immune pathway activation in response to infection and 
inflammation, particularly in sepsis and shock, is associated 
with increased activity of iNOS, and thus more NO being 
released [20, 71]. However, studies in experimental animals 
reveal that iNOS upregulation and production of NO may 
have a feedback inhibition on constitutive NO production in 
other tissues [21, 72]. Urinary NOx reflects both the 
production and utilization of NO [73, 74]. Nitrate is the main 
urinary NO metabolite, whereas nitrite is low to undetectable 
in urine [75]. Sepsis and shock can expose the kidney to 
ischemic injury and this can be reflected in low levels of 
uNOx excretion likely due to low endogenous NO 
generation [4, 66]. Conversely, since the majority (96%) of 
filtered nitrate and nitrite is reabsorbed by the renal tubules, 
high levels in urine secondary to reduced renal reabsorption 
may reflect acute renal failure concomitant with sepsis/septic 
shock [4, 76].  
 Although NO directly as well as by conversion to 
peroxynitrite can be bactericidal, excessive levels are 
counterproductive as evidenced by the refractory 
vasodilation, hypotension and decreased tissue perfusion [6]. 
Irrespective of mechanism and level of metabolite, NO as a 
downstream effector of innate immune activation lends itself 
as a potential biomarker for sepsis and septic shock. This 
may be particularly useful in the acute setting as the 
concentration of NOx in plasma or urine may predict 
important in-patient clinical outcomes, such as need for 
hospitalization, level of support (intensive care versus 
regular floor), and mortality. 
NO and its Metabolites in Acute Myocardial Infarction: 
Going Beyond Diagnostic Biomarkers to Therapeutic 
Intervention 
 As stated at the outset a continuous endogenous supply of 
NO is crucial for the physiological integrity of the 
cardiovascular system. In fact, an imbalance in the 
production or bioavailability of NO is unequivocally linked 
to cardiovascular pathology. With more recent advances in 
establishing the nitrate-nitrite-NO pathway, the reverse 
pathway that enables more NO to be generated when 
endogenous NOS pathways are dysfunctional, harnessing it 
therapeutically in prevention and treatment of cardiovascular 
disease becomes self-evident [77-79]. Ischemic heart disease 
is a major player in the acute care setting. In this disease 
process where regional hypoxia and ischemia prevail, it may 
be of great benefit to replenish the stores of NOx either 
pharmacologically or through diet [77, 78]. In the past, 
dietary NOx had been granted pariah status because of 
nebulous links to disease [78]. With greater evidence 
suggesting benefits of the oxidative NO metabolites in 
ischemia/reperfusion injury, a real paradigm shift is needed 
in the scientific community from the perspective of the 
relatively simple inorganic anions nitrate and nitrite. Nitrite, 
in fact, may be the endocrine mediator of NO-based 
signaling [80]. Bolusing nitrite intravenously prior to 
instigating a cardiovascular insult has been shown to 
significantly reduce the injury not only from myocardial 
infarction, but also ischemic liver and kidney injury and 
stroke in multiple animal models [81-84]. These pre-clinical 
or benchwork-based experiments have prompted several 
human clinical trials on NOx for cardiovascular 
complications like acute ischemia. In a very promising study 
nitrite therapy was shown to improve cardiac and 
neurological function and overall survival post cardiac arrest 
[85]. Initiating NOx-based clinical efficacy trials in the acute 
setting are justified since that is where cardiovascular 
complications like acute MI and cardiac arrest are first 
encountered by the medical team. These interventions will 
likely improve acute care management from the 
cardiovascular morbidity and mortality perspective.  
CONCLUSIONS AND FUTURE DIRECTIONS: 
ACUTE CARE AND BEYOND  
 This review has focused on the role of NO and its 
metabolites in a few disease processes commonly 
encountered in the acute care setting (sumarized in Fig. 2). 
We have argued that NO and its metabolites nitrate and 
nitrite can be potential biomarkers that need to be developed 
further from a diagnostic and prognostic perspective and that 
is likely to improve management in the acute care setting. 
Measured exhaled NO (feNO) concentration is immediately 
available and may be a reliable tool for assessment of airway 
inflammation in an acute asthma exacerbation. Concentration 
of NOx in multiple biological samples (plasma, urine, nasal 
secretion, CSF) measured via HPLC can also be reliably 
obtained in a rapid manner since the HPLC run per sample 
takes an average of 8 minutes [8]. Samples can be batched 
and run on the HPLC. Hence, both NO and NOx have the 
potential of being rapidly determined biomarkers for 
multiple disease processes encountered in the acute care 
setting (summarized in Fig. 2).  
 There are limitations to using NO and it’s metabolites as 
biomarkers. Although NOx can give a fairly reliable idea of 
systemic NO bioavailability, its concentration in urine and 
plasma being heavily dependent on renal activity, it cannot 
be an entirely accurate measure of NOS functionality. 
Additionally, the presence of nitrite and nitrate in everyday 
diet adds another restriction towards using NOx in plasma 
and urine as absolutely indicative of disease process [8]. 
Single feNO or NOx determinations simply may not be 
enough. Thus, sequential measurements of the biomarkers 
may be needed to get a better handle on the evolution of the 
disease process, initially as the patient presents in the acute 
phase and then during the course of critical care. Further, 
sampling from multiple compartments may be more 
informative of the disease process. For instance, for AKI, 
plasma and urinary NOx measurements simultaneously 
would enable us to determine the fractional excretion of 
urinary NO metabolites, potentially a more informative 
parameter for the disease entity than urinary NOx alone.  
 Given the non-specific nature of NO and its metabolites, 
they will be unlikely to entirely replace pre-existing tests. 
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Hence, this type of analysis should be in addition to the 
standard diagnostics and biomarkers. Having a more 
comprehensive picture will only improve diagnosis, 
prognosis and effectiveness of treatment and reveal how NO 
is or may be playing a role in the acute disease process. NO-
based analyses might not be able to differentiate between 
primary pulmonary versus cardiac disease. However, in the 
setting of a relevant clinical presentation and work up, 
analyzing NO and metabolites might be a valuable 
assessment for a NO component, and as such, an adjunct.  
 General state of health and co-morbid disease states 
might influence results, and hence have significant 
limitations on the use of NO or NO metabolites as 
biomarkers. Dietary NOx, as alluded to above, is a 
potentially significant limitation due to the fact that in the 
ED and critical care settings we cannot always predict or 
select patients based on fasted states or dietary patterns.  
 There is obvious value in obtaining a non-invasive 
specimen for determining levels of biomarkers for disease 
states. This will require the development, validation and then 
clinical usage of relatively simple, rapid and cost-effective 
techniques that may sample multiple body fluids collected 
non-invasively, such as nasal washes, saliva and urine [86]. 
Future studies will improve our understanding of NO 
pathophysiology and thus enable us to rationally devise 
pharmacological treatment for manipulating NO in acute 
disease states. While many of these therapeutic approaches 
remain speculative, better understanding of the underlying 
mechanisms that regulate NO function will ultimately 
improve our ability to implement such therapies. Adaptation 
to and validation of a point-of-care test with the assistance of 
an industry partner will enable inexpensive screening 
capacity on a dipstick, point-of-care type of a platform, to 
aid treatment decisions [87]. This has obvious global health 
implications that go far beyond any specific clinical setting 
[87].  
 Overall, what is most importantly highlighted, for acute 
care and non-acute care physicians alike, is the ongoing 
research need to determine the physiological roles of NOx, 
and if it can be used unequivocally both as diagnostic 
biomarker of disease and for treatment regimens, in a variety 
of clinical settings.  
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